everolimus

基本解释

In the treatment group, everolimus was introduced five weeks posttransplantation.
移植后实验组大鼠给予依维莫司5周。
Everolimus leads to a prolongation of allograft survival, reduced cell infiltrate in the graft, and prevents tubular atrophy and interstitial fibrosis.
依维莫司能够延长移植物的存活，减少移植物细胞浸润，防止小管萎缩及间质纤维化。
In the everolimus group, five of six animals survived for 20 weeks with stable serum creatinine and displayed neither acute cellular rejection nor CAN.
而在依维莫司组，六分之五的大鼠存活超过20周，血肌酐水平平稳，且既没有表现出急性细胞性排斥也没有CAN表现。
The aim of this study is to evaluate the therapeutic effect of everolimus on cellular and humoral mechanisms of chronic allograft damage in a rat model with sensitized recipients.
该研究的目的在于评估依维莫司对于细胞免疫和体液免疫导致的致敏大鼠肾移植模型慢性移植物肾病的作用。
CONCLUSION: The used rat model offers the opportunity to study the influence of everolimus on the interaction of humoral and cellular mechanisms involved in chronic renal damage.
结论：该大鼠模型研究慢性肾脏破坏体液和细胞机制，并研究依维莫司与其的交互作用。